| 臺大學術典藏 |
2018-09-10T18:07:35Z |
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
|
Nash, P. and Kirkham, B. and Okada, M. and Rahman, P. and Combe, B. and Burmester, G.-R. and Adams, D.H. and Kerr, L. and Lee, C. and Shuler, C.L. and Genovese, M. and Ahmed, K. and Alper, J. and Barkham, N. and Bennett, R.E. and Garc\\'ia, F.J.B. and Alonso, R.B. and Blumstein, H.B. and Brooks, M.S. and Burmester, G.-R. and Cagnoli, P. and Caldron, P.H. and Cantagrel, A. and Chen, D.-Y. and Churchill, M.A. and Codding, C.E. and Combe, B. and Deane, P.M.G. and Del Giudice, J. and Deodhar, A.A. and Dhar, R.K. and Dokoupilova, E. and Egan, R.M. and Everding, A. and Gal\\'indez, E. and Genovese, M. and Goddard, D.H. and Gottlieb, A. and Goupille, P. and Griffin, R.M. and Gupta, R.C. and Hall, S. and Hatti, K. and Howell, M.P. and Huang, Y.-H. and Jajoo, R. and Janssen, N.M. and Kiltz, U. and Kivitz, A.J. and Klein, S.J. and Korkosz, M.P. and Kotha, R. and Kremer, J.M. and Lue, C. and de la Fuente, J.L.M. and Marzo-Ortega, H. and Masmitja, J.G. and Mease, P.J. and Meroni, P.L. and Mueller, E.C. and Nandagudi, A.C. and Nash, P. and Fern\\'andez-Nebro, A. and Neuwelt, C.M. and Orbai, A.M. and Oza, M.R. and Parks, D.L. and Pattanaik, D. and Rell-Bakalarska, M.E. and Rosmarin, D. and Roussou, E. and Rychlewska-Hanczewksa, A.I. and Sikes, D.H. and Stack, M.T. and Sunkureddi, P. and Tahir, H. and Tha?i, D. and Tsai, T.-F. and Turkiewicz, A.M. and Unger, L. and Cabello, R.V. and Wagner, U. and Wei, C.-C. and Wells, A.F. and Youssef, P. and Zielinska, A.; TSEN-FANG TSAI |
